Free Trial

Viatris (VTRS) Stock Forecast & Price Target

Viatris logo
$9.15 -0.29 (-3.07%)
Closing price 03/21/2025 04:00 PM Eastern
Extended Trading
$9.28 +0.14 (+1.48%)
As of 03/21/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Viatris - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
2
Hold
1
Buy
1

Based on 4 Wall Street analysts who have issued ratings for Viatris in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 4 analysts, 2 have given a sell rating, 1 has given a hold rating, and 1 has given a buy rating for VTRS.

Consensus Price Target

$10.50
14.75% Upside
According to the 4 analysts' twelve-month price targets for Viatris, the average price target is $10.50. The highest price target for VTRS is $13.00, while the lowest price target for VTRS is $9.00. The average price target represents a forecasted upside of 14.75% from the current price of $9.15.
Get the Latest News and Ratings for VTRS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Viatris and its competitors.

Sign Up

VTRS Analyst Ratings Over Time

TypeCurrent Forecast
3/23/24 to 3/23/25
1 Month Ago
2/22/24 to 2/21/25
3 Months Ago
12/24/23 to 12/23/24
1 Year Ago
3/24/23 to 3/23/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
0 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
2 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$10.50$13.67$13.67$10.33
Forecasted Upside14.75% Upside21.48% Upside9.42% Upside-12.73% Downside
Consensus Rating
Reduce
Hold
Hold
Sell
Remove Ads

VTRS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

VTRS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Viatris Stock vs. The Competition

TypeViatrisMedical CompaniesS&P 500
Consensus Rating Score
1.75
2.82
2.54
Consensus RatingReduceModerate BuyModerate Buy
Predicted Upside14.75% Upside21,753.34% Upside18.90% Upside
News Sentiment Rating
Neutral News

See Recent VTRS News
Positive News
Positive News
Remove Ads
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/7/2025Jefferies Financial Group
2 of 5 stars
Glen Santangelo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$15.00 ➝ $13.00+35.77%
3/5/2025Piper Sandler
2 of 5 stars
David Amsellem
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$14.00 ➝ $10.00+4.22%
2/28/2025Barclays
3 of 5 stars
Balaji Prasad
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetUnderweight ➝ Underweight$12.00 ➝ $9.00-2.49%
2/28/2025Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jason Gerberry
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetUnderperform ➝ Underperform$11.00 ➝ $10.00+4.93%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 03:38 PM ET.


VTRS Forecast - Frequently Asked Questions

According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Viatris is $10.50, with a high forecast of $13.00 and a low forecast of $9.00.

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Viatris in the last twelve months. There are currently 2 sell ratings, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "reduce" VTRS shares.

According to analysts, Viatris's stock has a predicted upside of 14.75% based on their 12-month stock forecasts.

Viatris has been rated by research analysts at Bank of America, Barclays, Jefferies Financial Group, and Piper Sandler in the past 90 days.

Analysts like Viatris less than other "medical" companies. The consensus rating for Viatris is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how VTRS compares to other companies.


This page (NASDAQ:VTRS) was last updated on 3/23/2025 by MarketBeat.com Staff
From Our Partners